PolyPid (PYPD) Expected to Announce Quarterly Earnings on Wednesday

PolyPid (NASDAQ:PYPD) is expected to be issuing its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.54) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 8:30 AM ET.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.25).

PolyPid Price Performance

Shares of NASDAQ:PYPD opened at $3.84 on Wednesday. The firm has a fifty day moving average price of $3.44 and a two-hundred day moving average price of $3.31. PolyPid has a one year low of $2.30 and a one year high of $3.93. The company has a market cap of $61.06 million, a price-to-earnings ratio of -1.00 and a beta of 1.53.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PYPD. Craig Hallum reaffirmed a “buy” rating and issued a $13.00 price target (down previously from $15.00) on shares of PolyPid in a report on Thursday, August 14th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of PolyPid in a report on Wednesday, August 13th. Roth Capital reaffirmed a “buy” rating on shares of PolyPid in a report on Thursday, August 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PolyPid in a report on Wednesday, October 8th. Finally, Wall Street Zen raised PolyPid from a “sell” rating to a “hold” rating in a report on Friday, September 26th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.40.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.